Rübe C, Busch M, Willich N, Hess F, Schönekäs K, Kaudewitz P, Wendt T, Feist H, Dühmke E
Klinik und Poliklinik für Strahlentherapie-Radioonkologie, Westfälische Wilhelms-Universität Münster.
Strahlenther Onkol. 1996 Feb;172(2):74-80.
Patients with cutaneous T-cell lymphoma are treated in Germany mostly by dermatological local therapy like corticosteroids or PUVA-irradiation. Total skin electron beam irradiation is used rarely, even though it has a potentially curative character. We present an analysis of patients, who received a total skin electron beam irradiation after having progressive disease following other treatment modalities.
Twenty-one patients (mean age 58.9 years) in different stages were treated (stage IB and IIA n = 4, stage IIB n = 8, stage III n = 3, stage IV n = 6). All patients had progressive disease under other forms of local therapy. The irradiation was performed from 6 directions per hemibody using 2 axial fields which have each an 18 degree angle to the horizontal level. Six and 7 MeV fast electrons were used. Total dose was between 8 and 36 Gy in single dosis of 1 x 4 up to 5 x 2 Gy per week. In underdosed areas and areas of tumors of the skin boost irradiation with small fields was given.
All patients had a good tumor regression (complete remission: n = 10, partial remission: n = 11). With the follow-up between 4 and 93 months total- and recurrence-free survival was 18 and 7 months (median). Patients in early stages with slow but complete remission of the symptoms had the best prognosis. Because of the small case number there was no significant difference between the groups. There were no severe side effects of the radiotherapy noted.
Our analysis shows on a small patient number, that total skin electron beam irradiation has a good palliative effect on patients who have progressive disease following other types of treatment like PUVA or corticosteroids. The recurrence-free survival of 2 out of 4 patients with early stage disease (I-IIA) up to 93 month shows the potentially curative character of the treatment.
在德国,皮肤T细胞淋巴瘤患者大多接受皮肤科局部治疗,如使用皮质类固醇或补骨脂素紫外线A辐射(PUVA)照射。尽管全身皮肤电子束照射具有潜在的治愈性,但很少使用。我们对在接受其他治疗方式后病情进展的患者进行全身皮肤电子束照射的情况进行了分析。
对21例不同分期的患者(平均年龄58.9岁)进行了治疗(IB期和IIA期4例,IIB期8例,III期3例,IV期6例)。所有患者在其他形式的局部治疗下病情均有进展。使用2个与水平层面呈18度角的轴向野,从每个半侧身体的6个方向进行照射。使用6和7兆电子伏特的快电子。总剂量在8至36戈瑞之间,每周单次剂量为1×4至5×2戈瑞。对剂量不足的区域和皮肤肿瘤区域给予小野增强照射。
所有患者肿瘤均有良好消退(完全缓解:10例,部分缓解:11例)。随访4至93个月,总生存期和无复发生存期分别为18个月和7个月(中位数)。症状缓解缓慢但完全缓解的早期患者预后最佳。由于病例数较少,各组之间无显著差异。未观察到放疗的严重副作用。
我们的分析显示,在小样本患者中,全身皮肤电子束照射对在接受PUVA或皮质类固醇等其他类型治疗后病情进展的患者具有良好的姑息作用。4例早期疾病(I-IIA期)患者中有2例无复发生存期长达93个月,显示了该治疗的潜在治愈性。